Vor Biopharma Appoints Experienced Pharma CEO David Zaccardelli to Board
VOR has more than doubled off its 52-week low of $6.5.
Summary
Vor Biopharma appointed David Zaccardelli, a veteran pharmaceutical CEO with M&A experience, to its board, following a routine director resignation.
Key Events · Executive and Board Changes · VOR
-
Director Resignation
Andrew Levin, M.D., Ph.D., resigned from the Board of Directors, effective July 6, 2026. The company stated his resignation was not due to any disagreement.
-
New Director Appointment
David Zaccardelli, Pharm.D., was appointed as an independent Class II director, effective July 7, 2026, filling the vacancy created by Dr. Levin's resignation.
-
Extensive Industry Experience
Dr. Zaccardelli brings significant experience, having served as President and CEO of multiple public pharmaceutical companies (Verona Pharma, Dova Pharmaceuticals, Cempra Pharmaceuticals) that were subsequently acquired.
-
Compensation Package
Dr. Zaccardelli will receive an annual cash retainer of $40,000 and an initial stock option grant with an aggregate grant date fair value of $700,000.
Analysis · VOR · Life Sciences
Vor Biopharma has appointed David Zaccardelli, a seasoned pharmaceutical executive with a strong track record of leading and selling biotech companies, to its Board of Directors. His expertise in drug development and M&A could be highly beneficial for the company's strategic direction and future growth initiatives.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2797 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VOR was trading at $20.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.50 to $65.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.